140 related articles for article (PubMed ID: 19500259)
21. Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry.
Pina-Vaz C; Rodrigues AG; Costa-de-Oliveira S; Ricardo E; Mårdh PA
J Antimicrob Chemother; 2005 Oct; 56(4):678-85. PubMed ID: 16115827
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of anti-Candida potential of geranium oil constituents against clinical isolates of Candida albicans differentially sensitive to fluconazole: inhibition of growth, dimorphism and sensitization.
Zore GB; Thakre AD; Rathod V; Karuppayil SM
Mycoses; 2011 Jul; 54(4):e99-109. PubMed ID: 20337938
[TBL] [Abstract][Full Text] [Related]
23. [25S rDNA genotype and antifungal susceptibility of vaginal Candida albicans].
Zhang X; Liu ZH
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):279-84. PubMed ID: 27116986
[TBL] [Abstract][Full Text] [Related]
24. A D-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model.
Hayama K; Ishibashi H; Ishijima SA; Niimi K; Tansho S; Ono Y; Monk BC; Holmes AR; Harding DR; Cannon RD; Abe S
FEMS Microbiol Lett; 2012 Mar; 328(2):130-7. PubMed ID: 22211961
[TBL] [Abstract][Full Text] [Related]
25. Correlation of in vitro activity and in vivo efficacy of itraconazole intravenous and oral solubilized formulations by testing Candida strains with various itraconazole susceptibilities in a murine invasive infection.
Uchida K; Shimogawara K; Yamaguchi H
J Antimicrob Chemother; 2011 Mar; 66(3):626-34. PubMed ID: 21172782
[TBL] [Abstract][Full Text] [Related]
26. Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model.
Valentin A; Le Guennec R; Rodriguez E; Reynes J; Mallie M; Bastide JM
Antimicrob Agents Chemother; 1996 Jun; 40(6):1342-5. PubMed ID: 8725998
[TBL] [Abstract][Full Text] [Related]
27. A Case Report of Penile Infection Caused by Fluconazole- and Terbinafine-Resistant Candida albicans.
Hu Y; Hu Y; Lu Y; Huang S; Liu K; Han X; Mao Z; Wu Z; Zhou X
Mycopathologia; 2017 Apr; 182(3-4):397-402. PubMed ID: 27659805
[TBL] [Abstract][Full Text] [Related]
28. Variable antifungal susceptibility of wild-type Candida albicans phenotypes from neutropenic hosts.
Velegraki A; Papalambrou D; Soremi S; Legakis NJ
Eur J Clin Microbiol Infect Dis; 1996 Nov; 15(11):854-60. PubMed ID: 8997556
[TBL] [Abstract][Full Text] [Related]
29. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group.
Goldman M; Cloud GA; Smedema M; LeMonte A; Connolly P; McKinsey DS; Kauffman CA; Moskovitz B; Wheat LJ
Antimicrob Agents Chemother; 2000 Jun; 44(6):1585-7. PubMed ID: 10817713
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the fungitest kit by using strains from human immunodeficiency virus-infected patients: study of azole drug susceptibility.
Witthuhn F; Toubas D; Béguinot I; Aubert D; Rouger C; Remy G; Pinon JM
J Clin Microbiol; 1999 Mar; 37(3):864-6. PubMed ID: 9986878
[TBL] [Abstract][Full Text] [Related]
31. Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect.
Hope WW; Warn PA; Sharp A; Howard S; Kasai M; Louie A; Walsh TJ; Drusano GL; Denning DW
Antimicrob Agents Chemother; 2006 Nov; 50(11):3680-8. PubMed ID: 16954320
[TBL] [Abstract][Full Text] [Related]
32. Combination immunotherapy of MAb B6.1 with fluconazole augments therapeutic effect to disseminated candidiasis.
Lee JH; Jang EC; Han Y
Arch Pharm Res; 2011 Mar; 34(3):399-405. PubMed ID: 21547671
[TBL] [Abstract][Full Text] [Related]
33. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis.
Arthington-Skaggs BA; Warnock DW; Morrison CJ
Antimicrob Agents Chemother; 2000 Aug; 44(8):2081-5. PubMed ID: 10898679
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology of clinical isolates of Candida albicans and their susceptibility to triazoles.
Wroblewska MM; Swoboda-Kopec E; Rokosz A; Krawczyk E; Marchel H; Luczak M
Int J Antimicrob Agents; 2002 Dec; 20(6):472-5. PubMed ID: 12458145
[TBL] [Abstract][Full Text] [Related]
35. Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis.
Costa M; Passos XS; Miranda AT; de Araújo RS; Paula CR; Silva Mdo R
Mycopathologia; 2004 Jan; 157(1):43-7. PubMed ID: 15008344
[TBL] [Abstract][Full Text] [Related]
36. Is empiric therapy with fluconazole appropriate for esophageal candidiasis?
Sajith KG; Dutta AK; Sahni RD; Esakimuthu S; Chacko A
Indian J Gastroenterol; 2014 Mar; 33(2):165-8. PubMed ID: 24424852
[TBL] [Abstract][Full Text] [Related]
37. Trailing end-point phenotype antibiotic-sensitive strains of Candida albicans produce different amounts of aspartyl peptidases.
Braga-Silva LA; Mesquita DG; Ribeiro MD; Carvalho SM; Fracalanzza SE; Santos AL
Braz J Med Biol Res; 2009 Aug; 42(8):765-70. PubMed ID: 19649403
[TBL] [Abstract][Full Text] [Related]
38. In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling.
Andes D; Lepak A; Nett J; Lincoln L; Marchillo K
Antimicrob Agents Chemother; 2006 Jul; 50(7):2384-94. PubMed ID: 16801416
[TBL] [Abstract][Full Text] [Related]
39. Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.
Venisse N; Grégoire N; Marliat M; Couet W
Antimicrob Agents Chemother; 2008 Mar; 52(3):937-43. PubMed ID: 18180347
[TBL] [Abstract][Full Text] [Related]
40. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
Andes D; van Ogtrop M
Antimicrob Agents Chemother; 1999 Sep; 43(9):2116-20. PubMed ID: 10471550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
